| DRUG WATCH |
|
| Year : 2014 | Volume
: 46
| Issue : 5 | Page : 560-561 |
Levetiracetam induced acute reversible psychosis in a patient with uncontrolled seizures
Nithin Kumar1, HS Swaroop2, Ananya Chakraborty2, Suhas Chandran1
1 Department of Neurology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India
2 Department of Pharmacology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India
Correspondence Address:
Ananya Chakraborty
Department of Pharmacology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.140599
Levetiracetam (LEV) is a relatively newer antiepileptic drug with novel mechanism of action. It was introduced to the market in the year 2000. Pre-marketing clinical trials of the drug reported good tolerability with a wide safety margin. On post-marketing updates, there are few reports of psychosis after treatment with the drug. Here, we report a case of 52-year-old epileptic man who developed acute, reversible psychosis within 3 days of initiation of treatment. The drug was prescribed at a dose of 500 mg per day. After 3 days of treatment, the patient developed visual hallucinations, mood swings, withdrawal and suspicious behavior. Delirium was ruled out as there was no fluctuation in his sensorium or focal neurological deficits. His lab investigations for electrolytes, renal function test, thyroid, liver function and other related tests levels were within normal limits. A diagnosis of LEV induced psychosis was reached based on clinical judgment and causality assessment.
[FULL TEXT] [PDF]*
|
